Pulmonary Embolism in Critical Care Medicine

Sources: Braunwald's Heart Disease 12e, Fuster & Hurst's The Heart 15e, Fishman's Pulmonary Diseases & Disorders, Murray & Nadel's Respiratory Medicine, Miller's Anesthesia 10e, Goldman-Cecil Medicine, Harrison's Internal Medicine 22e (2025), and the brand-new 2026 AHA/ACC/ACCP/ACEP Guideline on Acute PE (PMID 41712677).

1. Overview and Epidemiology

• Virchow's Triad governs pathogenesis: stasis + vessel wall injury + hypercoagulability
• VTE is provoked when a temporary/reversible risk factor (surgery, trauma, immobilization, pregnancy) is present within 3 months of diagnosis
• VTE is unprovoked in the absence of such risks - a key prognostic distinction for anticoagulation duration

2. Risk Factors

3. Pathophysiology and Hemodynamic Consequences

1. Thrombus occludes pulmonary arterial branches → abrupt rise in pulmonary vascular resistance (PVR)
2. The RV - a thin-walled, low-pressure chamber - dilates and fails acutely when pulmonary artery mean pressure exceeds ~40 mmHg
3. RV dilation causes septal shift (D-sign) → impairs LV filling → low systemic output
4. RV wall tension rises → RV ischemia (troponin elevation reflects RV microinfarction)
5. Neurohumoral release of serotonin and thromboxane A2 causes pulmonary vasoconstriction, worsening PVR beyond the mechanical obstruction alone
6. The end result: obstructive cardiogenic shock with preserved (or even elevated) LV function

Key concept: Excessive IV fluid boluses may worsen RV failure in high-risk PE by causing further RV dilation and worsening septal shift. - Braunwald's Heart Disease, p. 1648

4. Classification (Risk Stratification)

• Braunwald's Heart Disease, p. 1643; Fuster & Hurst, p. 1764-1765

Biomarkers in Risk Stratification

• Troponin I or T: Elevated in RV microinfarction; predicts short-term mortality and adverse events
• BNP / NT-proBNP: Reflects RV wall stress; used alongside echo findings in intermediate-risk subclassification
• D-dimer: High sensitivity, low specificity; most useful for ruling out PE in low/intermediate pretest probability patients. Specificity drops to ~10% in patients >80 years old. Age-adjusted cutoff = age × 10 ng/mL (for patients >50 years)

5. Clinical Presentation

• Dyspnea (most common - often sudden onset)
• Pleuritic chest pain (suggests peripheral PE/infarction)
• Hemoptysis (pulmonary infarction)
• Syncope or presyncope (high-risk PE)
• Anxiety, sense of impending doom

• Tachycardia (most sensitive sign)
• Tachypnea
• Hypotension / shock (high-risk PE)
• Hypoxia, cyanosis
• JVD, RV S3 (RV failure)
• Unilateral leg swelling/tenderness (DVT source)
• Fever (pulmonary infarction with associated leukocytosis)

• Sinus tachycardia (most common)
• S1Q3T3 pattern
• New RBBB
• T-wave inversions V1-V4 (RV strain pattern)
• AF in massive PE

6. Diagnostic Approach

Step 1: Pretest Probability Assessment

• Score ≤4: PE unlikely (use D-dimer)
• Score >4: PE likely (proceed to imaging)

Step 2: D-Dimer

• Negative ELISA D-dimer (<500 ng/mL) in low/intermediate pretest probability excludes PE (sensitivity and NPV ≥95%)
• Can obviate CT in ~50% of outpatients and ~20% of inpatients
• Not useful in high-pretest-probability or critically ill patients (essentially always elevated)
• A pregnancy-adapted YEARS algorithm uses D-dimer cutoffs of 1000 ng/mL (if 0 YEARS criteria) or 500 ng/mL (if 1-3 criteria)

Step 3: Imaging

• First-line imaging modality when PE is suspected
• Directly visualizes thrombus
• Provides alternative diagnosis in ~40% of negative CTs
• Can assess RV:LV ratio (prognostic value)
• Limitation: contrast, radiation (breast dose concern in young women), and poor sensitivity for isolated subsegmental PE
• Negative predictive value >95% for clinically significant PE

• Preferred in young women, pregnancy (lower breast dose), and renal impairment
• High non-diagnostic rate limits utility (PIOPED study)
• SPECT V/Q overcomes many planar V/Q limitations

• NOT recommended as first-line diagnostic tool for PE
• Role: risk stratification, prognostication, and monitoring response to therapy once PE is confirmed
• Key echo findings of PE:
  • RV dilation (RV:LV ratio >0.9 on echo or CTPA = RV strain)
  • RV hypokinesis with apical sparing ("McConnell's sign" - though not pathognomonic)
  • Tricuspid regurgitation with elevated RVSP
  • Septal flattening / paradoxical septal motion (D-sign)
  • Thrombus in transit (rare but diagnostic)
  • IVC dilation without inspiratory collapse

• Diagnoses DVT (non-compressibility is primary criterion)
• If DVT confirmed in a patient with PE symptoms, diagnostic for VTE - anticoagulation warranted
• ~50% of CT-confirmed PE patients have no detectable lower-extremity DVT

• Fishman's Pulmonary Diseases, p. 511; Fuster & Hurst, pp. 1773-1782

7. Management

Immediate Supportive Care in the ICU

Renal insufficiency, hepatic dysfunction, and altered mentation are common systemic manifestations of high-risk PE due to low output state. - Braunwald's Heart Disease, p. 1648

Anticoagulation - The Foundation of All PE Management

• Preferred in massive PE, hemodynamically unstable patients, or when rapid reversal may be needed
• IV bolus: 80 units/kg, then infusion 18 units/kg/hr, titrated to aPTT 60-100 sec
• Advantage: immediate action, renal-independent clearance, reversible with protamine

• e.g., enoxaparin 1 mg/kg SC BID or 1.5 mg/kg SC daily
• Preferred for intermediate/low-risk PE if no renal failure
• More predictable pharmacokinetics than UFH

Advanced Therapy: When to Escalate Beyond Anticoagulation

A. Systemic Thrombolysis (Fibrinolysis)

• FDA-approved agent: Alteplase 100 mg IV over 2 hours (peripheral vein infusion; hold heparin during infusion)
• Indication: High-risk (massive) PE with hemodynamic compromise
• Benefits vs. anticoagulation alone (meta-analysis, N=2115): 47% reduction in all-cause mortality, 60% reduction in recurrent PE
• Risks: 2.7x increased major bleeding, 4.6x increased intracranial hemorrhage (1-3% rate)
• Patients benefit up to 14 days after symptom onset
• Half-dose (50 mg) alteplase: Associated with higher treatment escalation requirements (rescue thrombolysis 25.9% vs 7.3%) compared to full-dose; not recommended as a routine alternative
• Absolute contraindications: prior intracranial hemorrhage, ischemic stroke <3 months, known structural intracranial lesion, active internal bleeding (except menses), significant head trauma <3 months

B. Catheter-Directed Therapy (CDT)

1. Catheter-directed fibrinolysis (CDF): Low-dose t-PA infused directly into the thrombus via catheter in pulmonary artery
2. Ultrasound-facilitated CDT (USCDT): Ultrasound energy loosens thrombus architecture, improving t-PA penetration (EKOS system). Studied in SEATTLE II trial (N=150): 24 mg t-PA over 12-24h reduced RV:LV ratio by 25%, PA systolic pressure by 30%, no intracranial hemorrhage
3. Mechanical thrombectomy: No thrombolytics needed - ideal for contraindications to fibrinolysis
   • FlowTriever system (Inari Medical): Large-bore device with self-expanding nitinol disks + aspiration. In FLASH study (N=106, intermediate-risk PE): 25% reduction in RV:LV ratio, favorable safety profile

• Braunwald's Heart Disease, pp. 1649-1650

C. Surgical Pulmonary Embolectomy

• Indicated for: Massive PE failing or with contraindications to fibrinolysis; PE-in-transit with impending cardiovascular collapse
• Should be performed at experienced centers
• ECMO can bridge the patient to surgical embolectomy and can be continued postoperatively
• Mortality historically high but improving with PERT team co-management

D. Extracorporeal Membrane Oxygenation (ECMO)

• Role: Bridge therapy in catastrophic/super-massive PE with refractory shock or CPR
• Venoarterial (VA-ECMO) provides full cardiopulmonary support, allowing time for clot lysis or surgical embolectomy
• Can be deployed emergently by PERT teams
• Also useful intraoperatively and postoperatively during surgical embolectomy

• Sabiston Surgery; Braunwald's Heart Disease, p. 1648

Pulmonary Embolism Response Teams (PERTs)

• Pulmonology/critical care
• Interventional cardiology and radiology
• Cardiovascular surgery
• Hematology
• Emergency medicine

IVC Filter Placement

• Indications: Absolute contraindication to anticoagulation OR documented failure of anticoagulation
• Retrievable filters are preferred - retrieve when anticoagulation becomes safe
• IVC filters reduce short-term PE risk but are associated with increased long-term DVT risk
• NOT routinely indicated in PE patients who can be anticoagulated

8. Anticoagulation Duration

9. Special Considerations in the ICU

Mechanical Ventilation in PE

• Avoid high PEEP (increases RV afterload, worsens hemodynamics)
• Use lung-protective ventilation (TV 6 mL/kg IBW)
• Hypoxia in intubated PE patients may worsen significantly - monitor RV function

Monitoring Response to Therapy

• Decrease in HR, improvement in BP = early signs of success
• Serial echo: decline in RV:LV ratio is the key metric
• Troponin and BNP trends
• PA pressures via pulmonary artery catheter in refractory cases

Post-PE Syndrome

• ~50% of patients have residual symptoms (dyspnea, fatigue, exercise intolerance) at 6 months
• ~1% develop chronic thromboembolic pulmonary hypertension (CTEPH) - evaluate with V/Q scan at 3-6 months in symptomatic patients
• CTEPH is potentially curable with pulmonary thromboendarterectomy

10. PE in Pregnancy (Special Population)

• Leading cause of maternal mortality in the US (15% of maternal deaths 2003-2011)
• Risk ~5x higher than age-matched non-pregnant women
• Contributing factors: elevated coagulation factors (V, VIII, X, vWF), protein S fall, uterine IVC/left iliac vein compression, pelvic trauma at delivery
• Diagnosis: CTPA and V/Q scanning both feasible; V/Q preferred to reduce maternal breast radiation. Perfusion-only scan halves the fetal dose
• Anticoagulation: LMWH throughout pregnancy (DOACs contraindicated in pregnancy; warfarin teratogenic in first trimester)
• D-dimer unreliable in pregnancy (YEARS algorithm may help, but caution with missing PE remains paramount)

11. Key Clinical Pearls for Critical Care

1. Right heart failure, not hypoxia, is the primary cause of death in massive PE
2. Excessive fluids kill - conservative fluid management in RV failure
3. Echo is for risk stratification, not primary diagnosis - get CTPA first in most patients
4. CTPA is negative - still consider PE if clinical suspicion is very high (subsegmental PEs, poor study quality)
5. Thrombolysis in cardiac arrest from PE - administer empirically if PE suspected; continue CPR for at least 60-90 minutes after dosing
6. Half-dose alteplase is not equivalent to full-dose and requires more rescue therapy
7. PERT activation should be triggered early for any intermediate-high or high-risk PE
8. ECMO first, then sort - in catastrophic PE, stabilize with VA-ECMO before committing to thrombolysis vs. surgery

12. 2026 AHA/ACC Guideline Update - What's New

• New "AHA/ACC Acute PE Clinical Categories" replacing the older massive/submassive language with a more precise severity framework
• Stronger emphasis on evidence-based therapeutic decision-making using risk category
• Guidance on advanced interventional therapies including catheter-directed approaches and ECMO with clearer indications
• Updated recommendations on outpatient management for carefully selected low-risk patients
• Standardized approach to post-acute follow-up and CTEPH screening

This is the most comprehensive multi-society PE guideline published to date, covering evaluation, management, in-hospital support, and follow-up.